Spots Global Cancer Trial Database for envafolimab
Every month we try and update this database with for envafolimab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Total Neoadjuvant Therapy With Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Ultra Low Rectal Adenocarcinoma | NCT05858567 | Rectal Cancer | Envafolimab | 18 Years - | Sir Run Run Shaw Hospital | |
| Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer | NCT05298020 | Advanced Pancre... | Envafolimab Endostar Nab paclitaxel Gemcitabine | 18 Years - | The Affiliated Hospital of Xuzhou Medical University | |
| Total Neoadjuvant Therapy With Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Ultra Low Rectal Adenocarcinoma | NCT05858567 | Rectal Cancer | Envafolimab | 18 Years - | Sir Run Run Shaw Hospital | |
| Envafolimab Combined With Endostatin in Recurrent or Metastatic MSS-type Colorectal Cancer | NCT05551247 | Colorectal Neop... | Envafolimab recombinant hum... | 18 Years - 75 Years | First Affiliated Hospital Xi'an Jiaotong University | |
| A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer | NCT06010667 | Epithelial Ovar... | Envafolimab | 18 Years - 70 Years | Hebei Medical University Fourth Hospital | |
| Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC | NCT05910034 | Advanced Non-Sm... | Trilaciclib+Env... Envafolimab+Doc... Docetaxel | 18 Years - | Fudan University | |
| Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer | NCT05969847 | Rectal Cancer | split-course hy... CAPOX Envafolimab Local excision | 18 Years - 75 Years | Fujian Medical University Union Hospital | |
| Recombinant Human Endostatin Combined With Envafolimab and Synchronal Radiochemotherapy | NCT06279754 | Locally Advance... | Recombinant Hum... | 18 Years - 70 Years | The First Affiliated Hospital of Xinxiang Medical College | |
| A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors | NCT05615974 | Malignant Tumor... | LM101 Toripalimab Rituximab Envafolimab | 18 Years - | LaNova Medicines Limited | |
| A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma | NCT05941325 | Advanced or Unr... | fruquintinib Envafolimab | 12 Years - 70 Years | Shanghai 6th People's Hospital | |
| RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2 | NCT05417230 | Biliary Tract C... | RC48-ADC Envafolimab | 18 Years - | Jiangsu Cancer Institute & Hospital | |
| Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma (PRECAM) | NCT05216653 | MSS Locally Adv... | Envafolimab Oxaliplatin Capecitabine Short-course Ra... TME surgery, to... | 18 Years - | Sir Run Run Shaw Hospital | |
| Neoadjuvant Envafolimab in Resectable and Locally Advanced MSI-H/dMMR Rectal Cancer | NCT05645094 | Locally Advance... MSI-High | Envafolimab | 18 Years - 79 Years | Fudan University | |
| Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC. | NCT05068427 | Non Small Cell ... | Chidamide Envafolimab | 18 Years - | Chipscreen Biosciences, Ltd. | |
| ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors | NCT04891198 | Solid Tumor | Envafolimab | 18 Years - | 3D Medicines | |
| Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer | NCT06014372 | Colon Cancer Neoadjuvant The... Immunotherapy | Envafolimab CAPEOX | 18 Years - 75 Years | Sun Yat-sen University | |
| Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma | NCT05752136 | Rectal Cancer | Envafolimab | 18 Years - | Sir Run Run Shaw Hospital | |
| Total Neoadjuvant Therapy With Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Ultra Low Rectal Adenocarcinoma | NCT05858567 | Rectal Cancer | Envafolimab | 18 Years - | Sir Run Run Shaw Hospital | |
| YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma | NCT05448820 | Advanced Sarcom... Metastatic Sarc... Soft Tissue Sar... | YH001 Envafolimab Doxorubicin | 18 Years - | Tracon Pharmaceuticals Inc. | |
| Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer | NCT06014372 | Colon Cancer Neoadjuvant The... Immunotherapy | Envafolimab CAPEOX | 18 Years - 75 Years | Sun Yat-sen University | |
| Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical Cancer | NCT05799469 | Locally Advance... | Envafolimab Cisplatin External Beam R... Brachytherapy (... | 18 Years - 75 Years | Chongqing University Cancer Hospital | |
| Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC | NCT06123754 | Non-small Cell ... | Envalfolimab su... placebo subcuta... | 18 Years - | 3D Medicines | |
| Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer | NCT06014372 | Colon Cancer Neoadjuvant The... Immunotherapy | Envafolimab CAPEOX | 18 Years - 75 Years | Sun Yat-sen University | |
| Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC | NCT05910034 | Advanced Non-Sm... | Trilaciclib+Env... Envafolimab+Doc... Docetaxel | 18 Years - | Fudan University | |
| Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma | NCT05237349 | Metastatic or R... | Envafolimab Oxaliplatin S1 | 18 Years - 75 Years | Jiangsu Cancer Institute & Hospital | |
| Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC. | NCT05068427 | Non Small Cell ... | Chidamide Envafolimab | 18 Years - | Chipscreen Biosciences, Ltd. | |
| Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC | NCT06123754 | Non-small Cell ... | Envalfolimab su... placebo subcuta... | 18 Years - | 3D Medicines | |
| A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer | NCT05414630 | Non-small Cell ... | Envafolimab | 18 Years - | Anhui Provincial Cancer Hospital | |
| Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma | NCT05237349 | Metastatic or R... | Envafolimab Oxaliplatin S1 | 18 Years - 75 Years | Jiangsu Cancer Institute & Hospital | |
| RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2 | NCT05417230 | Biliary Tract C... | RC48-ADC Envafolimab | 18 Years - | Jiangsu Cancer Institute & Hospital | |
| A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLC | NCT05360979 | Non-small Cell ... | envafolimab | 18 Years - 70 Years | Second Xiangya Hospital of Central South University | |
| ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors | NCT04891198 | Solid Tumor | Envafolimab | 18 Years - | 3D Medicines | |
| Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLC | NCT05055167 | Non-small Cell ... | Envafolimab | 70 Years - | The First Affiliated Hospital of Xiamen University | |
| Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer | NCT05422183 | Ovarian Cancer,... | Envafolimab Lenvatinib VP-16 | 18 Years - | Zhongda Hospital | |
| Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma | NCT05752136 | Rectal Cancer | Envafolimab | 18 Years - | Sir Run Run Shaw Hospital | |
| A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer | NCT05414630 | Non-small Cell ... | Envafolimab | 18 Years - | Anhui Provincial Cancer Hospital | |
| ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma | NCT04480502 | Undifferentiate... Myxofibrosarcom... | Envafolimab Ipilimumab | 12 Years - | Tracon Pharmaceuticals Inc. | |
| A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer | NCT06010667 | Epithelial Ovar... | Envafolimab | 18 Years - 70 Years | Hebei Medical University Fourth Hospital | |
| Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer | NCT06014372 | Colon Cancer Neoadjuvant The... Immunotherapy | Envafolimab CAPEOX | 18 Years - 75 Years | Sun Yat-sen University | |
| Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma | NCT05552651 | Esophageal Squa... | Envafolimab Albumin-Bound P... Carboplatin | 18 Years - 75 Years | Air Force Military Medical University, China | |
| Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLC | NCT05055167 | Non-small Cell ... | Envafolimab | 70 Years - | The First Affiliated Hospital of Xiamen University | |
| To Determine the Efficacy and Safety of Envafolimab Combined With XELOX for Locally Advanced Colon Cancer | NCT05335460 | Colon Cancer | Envafolimab | 18 Years - 75 Years | Fujian Cancer Hospital | |
| Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients | NCT05213221 | Advanced Hepato... | Envafolimab TACE Lenvatinib | 18 Years - 75 Years | Zhejiang University | |
| Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC | NCT05203276 | Lung Neoplasms | Envafolimab Endostar | 18 Years - 80 Years | The First People's Hospital of Lianyungang |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
